SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of hands pointing to destination on globe
Business
Opinion: Investing in Research and Welcoming Global Talent Strengthens America
Recent decisions to reduce health and science research funding and limit the participation of international students and researchers could prove damaging in the short and long term.
June 4, 2025
 · 
4 min read
 · 
Dr. Chris Otiko
Podcast
M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama
Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over COVID-19 vaccine recommendations and several news outlets are questioning the validity of the White House’s Make America Healthy Again report.
June 4, 2025
 · 
2 min read
 · 
Heather McKenzie
Robotic claw clutching a money stock illustration
Cell therapy
Gilead Gears Up To Challenge J&J in $20B Multiple Myeloma CAR -T Market
J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at least as good efficacy.
June 4, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Big fish with a dollar badge wants to eat small fish
Deals
Pharma Tuck-In Deals Grow After a Mediocre First Quarter for Small Biotechs
Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical milestones on the horizon.
June 4, 2025
 · 
4 min read
 · 
Annalee Armstrong
Investor or businessman hand insert dollar coin in giant bomb with burning fuse. Risk and money management. Financial and economic crisis concept. flat vector illustration
Venture capitalists
Boom, Bust and Recover: What Happens Next as Biotech VC Cycle Resets
A new report from Pitchbook suggests we’re in for a period of more sustainable investing, with VC firms continuing to create and invest in companies, just more carefully.
June 4, 2025
 · 
3 min read
 · 
Annalee Armstrong
Composite photo collage of business people hands hold checkered flags success finish vote competition isolated on painted background.
Cancer
Kura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With Syndax
Kura Oncology won FDA priority review for its drug the day before announcing new data at ASCO 2025 showing remission in about one-quarter of patients.
June 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
People walking around a convention center
Editorial
The Decadent Show of Data at ASCO25
The cancer conference overwhelms the senses and shows off the might of the pharmaceutical industry.
June 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Art collage with male hand and graphs. Concept of business, finance, economy, professionalism and success. Symbolism and surrealism. Copy space.
Immunology and inflammation
Kymera Soars on Early Protein Degrader Data
The candidate is being positioned as a potential oral competitor to Sanofi and Regeneron’s blockbuster Dupixent in allergy and inflammation indications.
June 3, 2025
 · 
1 min read
 · 
David Adam
IV infusion set on yellow background, flat lay
Lung cancer
Roche and Jazz Link Drug Combo to Improved Survival in Phase III Lung Cancer Trial
Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could offer an alternative to monotherapy treatments from Roche and AstraZeneca.
June 3, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS